Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Immunocore, GlaxoSmithKline deal

Immunocore partnered with GlaxoSmithKline to use Immunocore's ImmTAC technology to discover and develop ImmTACs against multiple undisclosed targets selected

Read the full 192 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE